IPCA LABORATORIES
|
IPCA LABORATORIES Last 5 Year Financial Ratios History
[Consolidated]
| Mar2026 | Mar2025 | Mar2024 | Mar2023 | Mar2022 | |
|---|---|---|---|---|---|
| Operational & Financial Ratios | |||||
| Earnings Per Share (Rs) | 44.98 | 29.08 | 21.57 | 18.58 | 34.85 |
| CEPS(Rs) | 63.44 | 46.72 | 34.94 | 29.70 | 45.07 |
| DPS(Rs) | 6.00 | 4.00 | 4.00 | 4.00 | 4.00 |
| Book NAV/Share(Rs) | 317.72 | 273.78 | 249.53 | 230.27 | 215.41 |
| Tax Rate(%) | 24.24 | 30.38 | 37.20 | 33.99 | 19.79 |
| Margin Ratios | |||||
| Core EBITDA Margin(%) | 20.26 | 18.69 | 16.41 | 14.47 | 21.57 |
| EBIT Margin(%) | 17.12 | 13.64 | 12.76 | 12.71 | 19.67 |
| Pre Tax Margin(%) | 16.30 | 12.65 | 10.94 | 11.94 | 19.48 |
| PAT Margin (%) | 12.35 | 8.81 | 6.87 | 7.88 | 15.63 |
| Cash Profit Margin (%) | 16.68 | 13.26 | 11.50 | 12.07 | 19.61 |
| Performance Ratios | |||||
| ROA(%) | 9.89 | 6.90 | 5.37 | 6.06 | 13.31 |
| ROE(%) | 15.88 | 11.86 | 8.70 | 8.70 | 17.92 |
| ROCE(%) | 19.41 | 15.27 | 13.10 | 11.71 | 20.46 |
| Asset Turnover(x) | 0.80 | 0.78 | 0.78 | 0.77 | 0.85 |
| Sales/Fixed Asset(x) | 1.31 | 1.28 | 1.35 | 1.54 | 1.68 |
| Working Capital/Sales(x) | 2.37 | 2.50 | 2.42 | 1.85 | 1.96 |
| Efficiency Ratios | |||||
| Fixed Capital/Sales(x) | 0.76 | 0.78 | 0.74 | 0.65 | 0.60 |
| Receivable days | 73.75 | 72.89 | 63.37 | 55.52 | 53.92 |
| Inventory Days | 100.11 | 102.72 | 99.83 | 105.25 | 108.09 |
| Payable days | 131.14 | 121.11 | 102.19 | 86.04 | 111.16 |
| Valuation Parameters | |||||
| PER(x) | 35.64 | 51.63 | 57.39 | 43.62 | 30.45 |
| PCE(x) | 25.27 | 32.13 | 35.44 | 27.28 | 23.55 |
| Price/Book(x) | 5.05 | 5.48 | 4.96 | 3.52 | 4.93 |
| Yield(%) | 0.37 | 0.27 | 0.32 | 0.49 | 0.38 |
| EV/Net Sales(x) | 4.25 | 4.39 | 4.24 | 3.25 | 4.67 |
| EV/Core EBITDA(x) | 18.93 | 21.43 | 22.44 | 19.11 | 19.63 |
| EV/EBIT(x) | 24.71 | 32.03 | 33.05 | 25.41 | 23.60 |
| EV/CE(x) | 4.65 | 4.73 | 4.21 | 2.76 | 4.33 |
| M Cap / Sales | 4.24 | 4.28 | 4.10 | 3.31 | 4.64 |
| Growth Ratio | |||||
| Net Sales Growth(%) | 7.89 | 16.11 | 23.50 | 7.03 | 7.45 |
| Core EBITDA Growth(%) | 18.35 | 25.78 | 37.28 | -23.51 | -14.35 |
| EBIT Growth(%) | 35.49 | 23.95 | 23.94 | -30.82 | -18.15 |
| PAT Growth(%) | 51.28 | 48.81 | 7.58 | -46.00 | -20.71 |
| EPS Growth(%) | 54.69 | 34.77 | 16.13 | -46.69 | -61.22 |
| Financial Stability Ratios | |||||
| Total Debt/Equity(x) | 0.09 | 0.19 | 0.22 | 0.25 | 0.14 |
| Current Ratio(x) | 2.76 | 2.50 | 2.35 | 2.87 | 3.03 |
| Quick Ratio(x) | 1.58 | 1.43 | 1.30 | 1.91 | 1.77 |
| Interest Cover(x) | 20.88 | 13.88 | 6.99 | 16.47 | 102.40 |
| Total Debt/Mcap(x) | 0.02 | 0.03 | 0.04 | 0.07 | 0.03 |
Compare Financial Ratios of peers of IPCA LABORATORIES
| Peers & Returns | Market Capitalization | 1 Week | 1 Month | 1 Year | ||
| IPCA LABORATORIES | ₹44,825.0 Cr | 0.3% | -1.5% | 12.9% | Stock Analytics | |
| SUN PHARMACEUTICAL INDUSTRIES | ₹467,630.0 Cr | -2.6% | 2.4% | 14.6% | Stock Analytics | |
| DIVIS LABORATORIES | ₹221,666.0 Cr | 6.5% | 23.3% | 25.3% | Stock Analytics | |
| TORRENT PHARMACEUTICALS | ₹190,108.0 Cr | 2.6% | 3% | 33.5% | Stock Analytics | |
| CIPLA | ₹117,139.0 Cr | -1.1% | -0.2% | -7.9% | Stock Analytics | |
| DR REDDYS LABORATORIES | ₹97,990.9 Cr | 2.6% | -13.3% | -10.7% | Stock Analytics | |
IPCA LABORATORIES Share Price vs Sensex
| Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
| IPCA LABORATORIES | 0.3% |
-1.5% |
12.9% |
| SENSEX | 1.2% |
0.4% |
-2.9% |
You may also like the below Video Courses
